Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Linking shox/shox2 deficiency with fgfr3 gain-of-function and natriuretic peptides.

Created on 13 Sep 2026

Authors

Sandra Hoffmann, Sabrina Diebold, Ralph Roeth, Annette Löwen, Stefanie Mellein, Steffen Just, Gudrun A Rappold

Published in

Frontiers in endocrinology. Volume 17. Pages 1803846. Epub Apr 17, 2026.

Abstract

Short stature homeobox (SHOX) and its close paralogue SHOX2 are important transcriptional regulators of developmental processes. To understand how they function both individually and as an ensemble, we examined their mutual interdependence using zebrafish as a model. As both genes maintain important roles in various tissues, we assessed their expression patterns in the whole embryo as well as separately in fins, heart and brain. Fibroblast growth factor receptor 3 (FGFR3) is a direct target of SHOX, and FGFR3 mutations cause achondroplasia, a condition treatable with C-type natriuretic peptide (CNP) analogues. Building on this knowledge, we investigated how altered shox and shox2 expression relates to fgfr3 expression and the natriuretic peptide family (nppa, nppb, nppc) in zebrafish. Here, we demonstrate that shox and shox2 mutually regulate each other's expression in a tissue-specific manner. In brain and whole embryos their effects are additive and synergistic, while in fins and heart their combined actions become partially antagonistic. Distinct tissue-specific effects of shox and shox2 were also noted on natriuretic peptide gene activity. In the fin, shox knockdown reduces nppc transcript levels, whereas in heart tissue, deficiency of shox and shox2, particularly in the double knockdown, results in an increased expression of nppb, a known marker for cardiac stress. We also show that shox2 deficiency increases fgfr3 levels, which are reduced by CNP treatment. These results in zebrafish may have implications for other vertebrates, including humans with SHOX deficiency, who should be monitored for cardiac disease in later life, and those who have an inadequate response to growth hormone may profit from CNP therapy.

PMID:
42077444
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement